NeuroMarker for MCI/Alzheimer's
Early detection of Mild Cognitive Impairment (MCI) due to Alzheimer's disease
Pre-clinicalActive
Key Facts
Indication
Early detection of Mild Cognitive Impairment (MCI) due to Alzheimer's disease
Phase
Pre-clinical
Status
Active
Company
About Altoida
Altoida is pioneering a new category in neurological diagnostics with its multi-modal digital biomarker platform. The company's core technology, the NeuroMarker Platform, uses AR tasks and sensor fusion on a smart tablet to capture hundreds of data points, aiming to detect cognitive decline earlier and more reliably than traditional pen-and-paper methods. Founded in 2017 and based on over two decades of research, Altoida is initially targeting MCI and Alzheimer's, with plans to expand into other CNS diseases. The platform is currently investigational and is being utilized in pharmaceutical research for clinical trial support.
View full company profile